Welcome to our dedicated page for Hercules Capital news (Ticker: HTGC), a resource for investors and traders seeking the latest updates and insights on Hercules Capital stock.
Hercules Capital, Inc. (NYSE: HTGC) generates news that reflects its role as a specialty finance company focused on senior secured venture growth loans to high-growth, innovative companies in technology and life sciences industries. Company announcements and regulatory filings provide insight into its lending activity, capital markets presence, credit ratings, and shareholder distributions, all of which are relevant to investors tracking HTGC stock.
News about Hercules Capital often covers financing transactions with venture-backed companies, such as growth facilities and term loans that support corporate expansion, product development, or balance sheet restructuring. Public releases also highlight the company’s position as a financing partner to businesses in areas like finance automation, mental health therapeutics, and multifamily housing technology, illustrating how its venture growth loans are deployed in practice.
Another recurring theme in Hercules Capital’s news flow is its financial performance and distributions. The company reports quarterly results, including total investment income and other performance metrics, through earnings releases and related conference calls. It also announces quarterly cash distributions, describing its variable distribution policy and the breakdown of base and supplemental distributions, along with key record and payment dates.
Credit quality and ratings updates are also part of the HTGC news stream. Rating agencies such as Moody’s Investors Service and Kroll Bond Rating Agency have issued reports upgrading or affirming Hercules Capital’s investment grade ratings, citing factors such as its long operating history as a business development company, focus on senior secured venture debt, leverage profile, and access to capital markets.
For investors and analysts, following Hercules Capital news can provide context on its lending pipeline, portfolio activity, distribution decisions, and external credit assessments. This page aggregates these updates so readers can review company-specific developments and related commentary in one place.
enGene (Nasdaq: ENGN) reported Q1 2026 results and provided a development update for detalimogene voraplasmid. Key highlights: $312.5 million cash and marketable securities providing runway into 2H 2028, expanded $125 million Hercules debt facility, and $140.1 million net proceeds from a Nov 2025 offering.
LEGEND pivotal cohort showed promising efficacy (63% CR any time; 56% CR at 3 months; 62% CR at 6 months). enGene plans a BLA submission and expects 12-month data and a conference update in 2026.
Hercules Capital (NYSE: HCXY) announced that Morningstar DBRS affirmed its BBB (high) investment grade corporate and credit rating with a Stable trend on March 4, 2026. DBRS cited the company’s franchise strength, resilient earnings, sound asset credit performance, funding depth and disciplined leverage.
DBRS placed Hercules at the top end of its business development company peer-range and noted the company is positioned to weather volatility from moderating growth and AI-related sentiment, while its software originations focus on firms with domain expertise and higher switching costs.
Hercules Capital (NYSE:HCXY) was named 2025 BDC Manager of the Year - Americas by Private Debt Investor. The award recognizes Hercules’ strong 2025 performance across assets under management, new debt and equity commitments, gross fundings, net debt portfolio growth, and investment income.
Management cited record highs and consistent execution amid tight capital markets and slower fundraising.
Hercules Capital (NYSE: HTGC) reported record full-year 2025 results, with $3.92 billion of total new debt and equity commitments (+45.7% YoY) and $2.28 billion of total fundings (+25.9% YoY).
Other highlights include record full-year investment income of $532.5 million, net investment income of $341.7 million, Q4 commitments of $1.06 billion (+70.8% YoY), available liquidity of over $1.0 billion, undistributed earnings of $149.9 million (≈$0.82 per ending share), and approximately $5.7 billion of assets under management (+20.5% YoY). The company announced a new supplemental 2026 cash distribution of $0.28 per share.
Hercules Capital (NYSE: HTGC) closed an underwritten public offering of $300.0 million aggregate principal amount of unsecured 5.350% notes due February 10, 2029. The Notes pay interest semiannually and are redeemable at the company’s option at par plus a make-whole premium, if applicable.
The company assigned initial ratings of Baa2 by Moody’s and BBB- by Fitch. Net proceeds will fund investments, repay secured indebtedness and support general corporate purposes. Joint book-running managers included Goldman Sachs, SMBC Nikko and MUFG Securities.
Hercules Capital (HCXY) declared a new supplemental cash distribution totaling $0.28 per share, to be paid equally over four quarters beginning with $0.07 per share for Q4 2025. That Q4 supplemental payment has a record date Feb 25, 2026 and payment date March 4, 2026.
The $0.07 supplemental is in addition to the regular Q4 2025 quarterly distribution of $0.40 per share and will be paid from undistributed taxable income as of December 31, 2025. The company reports 78.54% Qualified Interest Income (QII) for 2025 distributions.
Hercules Capital (NYSE: HCXY) declared a $0.47 per share total cash distribution for Q4 2025, comprising a $0.40 base and a $0.07 supplemental.
Record date is February 25, 2026 and payment date is March 4, 2026. The company said 100% of Q4 distributions derived from current and accumulated earnings and profits, and QII for 2025 distributions is 78.54%.
Hercules Capital (NYSE: HTGC) priced an underwritten public offering of $300.0 million aggregate principal amount of 5.350% unsecured notes due February 10, 2029.
The notes bear interest at 5.350% payable semiannually, are expected to settle on February 10, 2026, and proceeds are planned to fund investments, repay secured indebtedness and for general corporate purposes.
Hercules Capital (NYSE: HCXY) scheduled its fourth-quarter and full-year 2025 results release and conference call for Thursday, February 12, 2026. Results will be released after market close and a conference call will follow at 2:00 p.m. PT / 5:00 p.m. ET.
The live webcast and archived replay will be available on the Investor Resources page at investor.htgc.com. Domestic and international dial‑in numbers are provided, and callers should reference conference ID HTGCQ425.
Savara (Nasdaq:SVRA) amended its loan and security agreement with Hercules Capital (NYSE:HTGC) to make up to $75 million of additional debt available upon U.S. FDA approval of MOLBREEVI, an investigational therapy for autoimmune pulmonary alveolar proteinosis.
Combined with a previously announced $75 million royalty financing, the company would have access to approximately $150 million of non-dilutive capital to support a potential MOLBREEVI launch. Savara resubmitted the MOLBREEVI BLA in December 2025, is targeting potential approval in 3Q 2026 if Priority Review is granted, and expects to file EU/UK MAA by end of 1Q 2026.